Quality assurance and cancer medicines in low-income and middle-income countries

Lancet Oncol. 2021 Mar;22(3):301-303. doi: 10.1016/S1470-2045(21)00055-3.
No abstract available

MeSH terms

  • Antineoplastic Agents / standards*
  • Antineoplastic Agents / therapeutic use
  • Developing Countries*
  • Humans
  • Income*
  • Neoplasms / drug therapy*
  • Neoplasms / economics*
  • Poverty
  • Practice Patterns, Physicians' / standards*
  • Quality Assurance, Health Care / standards*
  • Therapeutic Equivalency

Substances

  • Antineoplastic Agents